Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Lymphoma, Ovarian Cancer, Prostate Cancer
Conditions
Keywords
Geriatric oncology, Intervention, Case management
Brief summary
Randomized trials have already demonstrated that geriatric intervention was able to improve survival in the general elderly population but only a few have been performed in cancer patients. At the end, these data are not sufficient to consider geriatric intervention as validated in this setting. Case Management, coordinated by a geriatrician and a trained nurse, could improve prognosis of elderly patients with cancer. This approach, can be integrated in daily oncology practice. This strategy will be compared to usual oncological management in a randomized phase III trial.
Detailed description
Patients will first be screened using the G8 screening tool. If the resulting score is altered (G8 \<= 14), patients will be included in the main study and randomized according to 2 modalities: Arm A / Usual care (treatment according to on-going regimens in oncology) or Arm B /Case management (assessment of the patient by the nurse and the geriatrician with interventions as prescribed by the geriatrician). The intervention will be considered effective if, at one year, compared to usual care there is a significant clinical improvement in overall survival (OS) without a significant deterioration or/and clinical improvement of at least one of the targeted quality of life (QoL) scores, without significant clinical deterioration in at least one of the targeted QoL scores and without significant difference in OS in favor of usual care. If the resulting score is normal (G8 \> 14), patients will be treated according to their physician-in-charge opinion. A minimal set of data will be collected (age, sex, tumor type, disease stage, performance status (PS), creatinine clearance, albumin and C-Reactive Protein (CRP) levels mainly) to allow for the characterization of the population in order to compare our results to those of other published series.
Interventions
OTHERGeriatrician Intervention
Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
Sponsors
Institut Bergonié
Ministry of Health, France
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient older 70 years and older 2. Performance status 0 to 3 (WHO) 3. G8 and QLQ-C30 questionnaires 'score are available 4. No previous geriatric evaluation during cancer treatment 5. Locally advanced or metastatic disease : 1. 1st line medical treatment : * Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative, * Colon and rectum : metastatic (unresectable metastasis), * Prostate cancer : metastatic and refractory to hormonal castration, * Bladder cancer : locally advanced or metastatic, * Ovarian cancer : advanced stage (IIb to IV), * Lung cancer : metastatic non-small cell, * Lymphomas (indolent and aggressive) 2. Or 2nd line medical treatment : * Breast cancer : locally advanced or metastatic disease, hormone-resistant and Her2 negative, * Colon and rectum : metastatic (unresectable metastasis), * Prostate cancer : metastatic and refractory to hormonal castration, * Ovarian cancer : advanced stage (IIb to IV), * Lymphomas (indolent and aggressive) 6. Life expectancy over 6 months 7. Signed informed consent 8. Patients with a French social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code).
Exclusion criteria
1. Patient who already received 2 medical treatment lines 2. Exclusive 1st or 2nd treatment lines of : * Hormonotherapy (except for prostate cancer : abiteratone acetate is allowed), * Surgery, * Radiotherapy, 3. "Best supportive care" treatment 4. Patient unable to understand quality of life questionnaire 5. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons. 6. Patient placed under guardianship 7. Planned concomitant participation to another medical interventional trial during the 12 months following the inclusion in the randomized study PREPARE 8. Previous enrolment in the present study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival defined as the delay between randomization and death, all causes. | Year 1 |
| Health related quality of life (HR-QoL) assessed using 3 scales of European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire. | Year 1 |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival defined as the delay between randomization and death, all causes. | Year 3 |
| Health related quality of life (hRQoL) assessed using 3 scales of EORTC QLQ-C30 questionnaire. | Year 3 |
| 6-month response rates defined as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or Cheson criteria. | Month 6 |
| Toxicity graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4. | up to 3 years |
| Number of unscheduled hospitalizations. | up to 3 years |
| Length of unscheduled hospitalizations. | up to 3 years |
| For the experimental arm only: Assessment of autonomy using Activities of Daily Living (ADL) questionnaire. | Months 0, 6, 12 |
| For the experimental arm only: Assessment of autonomy using Instrumental Activities of Daily Living (IADL) questionnaire. | Months 0, 6, 12 |
| For the experimental arm only: Assessment of depression using Geriatric Depression Scale (GDS-15) scale. | Months 0, 6, 12 |
| For the experimental arm only: Assessment of cognitive functions using mini mental state exam (MMSE). | Months 0, 6, 12 |
| For the experimental arm only: Assessment of comorbidities using Cumulative Illness Rating Scale for Geriatrics (CIRS-G) scale. | Months 0, 6, 12 |
| For the experimental arm only: Assessment of nutritional status using mini nutritional assessment (MNA) scale. | Months 0, 6, 12 |
| For the experimental arm only: Assessment of mobility using get-up and Go test. | Months 0, 6, 12 |
Countries
France
Contacts
STUDY_CHAIRPierre-Louis SOUBEYRAN, PU-PH
Institut Bergonié
Outcome results
None listed